


New Australian collaboration to advance gene and cell therapy sector

22 July 2025 | News

Expanding access to ATMPs for both Australian and International patients through clinical trials



Australia-based contract development and manufacturing organisations Viral Vector Manufacturing Facility (VVMF) and Cell Therapies have co-signed a Memorandum of Understanding (MoU) to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products (ATMPs).

This partnership underscores a shared commitment to expanding access to ATMPs for both Australian and International patients through clinical trials.

The MoU also affirms joint efforts to advance capabilities across Australia's cell and gene therapy (CGT) sector – bolstering support for the growing global CGT market and driving innovation and manufacturing capacity for the Asia Pacific (APAC) region.

Stephen Thompson, VVMF CEO, said, “VVMF is proud to collaborate with Cell Therapies, Australia's leading capability in cell therapy manufacturing. Our complementary strengths and services reinforce Australia's unique biomanufacturing ecosystem and showcase why Australia is a premier destination for the development and production of cell and gene therapies. Together we are committed to improving outcomes for patients, customers, and partners across Australia, the APAC region, and globally”

Bev Menner, Cell Therapies CEO, said, “This collaboration advances efforts to secure a fully integrated onshore value chain for advanced therapies in Australia—enhancing patient access to cutting-edge treatments, reinforcing clinical trial and translational capabilities, and enabling export-readiness across the APAC region. Strategic investment in sovereign manufacturing capacity for CGTs and critical inputs positions Australia to compete in the global advanced therapies market.”